[go: up one dir, main page]

WO2003035090A1 - Agents soulageant les reactions allergiques anaphylactiques, et leur procede de production - Google Patents

Agents soulageant les reactions allergiques anaphylactiques, et leur procede de production Download PDF

Info

Publication number
WO2003035090A1
WO2003035090A1 PCT/JP2002/010918 JP0210918W WO03035090A1 WO 2003035090 A1 WO2003035090 A1 WO 2003035090A1 JP 0210918 W JP0210918 W JP 0210918W WO 03035090 A1 WO03035090 A1 WO 03035090A1
Authority
WO
WIPO (PCT)
Prior art keywords
stevia
producing
anaphylactic
extract
filtrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/010918
Other languages
English (en)
Japanese (ja)
Inventor
Tatsuhiko Kon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THIEISUTEBIA KK
Original Assignee
THIEISUTEBIA KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THIEISUTEBIA KK filed Critical THIEISUTEBIA KK
Publication of WO2003035090A1 publication Critical patent/WO2003035090A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to a anaphylaxis-type allergic symptom ameliorating substance which is a cause of hay fever, measles measles, bronchial asthma, atopic disease and the like and a method for producing the same.
  • Anaphylaxis generally refers to a systemic allergic reaction triggered by immunological mechanisms.
  • histamine and leukotriene are released from mast cells or basophils throughout the body due to allergic reactions of type I, ie, anaphylaxis, mediated by IgE antibodies. It is thought to cause bronchial asthma.
  • type I ie, anaphylaxis
  • the therapeutic agent, oral medicine, and substance having an antihistamine effect obtained by fermenting the plant tissue of Stevia require a long period of 90 days or more to ferment the plant tissue.
  • An object of the present invention is to obtain a novel substance that improves the symptoms of anaphylactic allergy by shortening the period required for fermentation of stevia extract extracted from plant tissue of stevia, and to obtain the novel substance. Providing new manufacturing methods The purpose is to do so. Disclosure of the invention
  • the anaphylactic allergic symptom improving substance of the present invention is obtained by adding yeast to a stevia extract extracted from a plant tissue of stevia and fermenting the extract.
  • the stevia plant tissue is stevia leaves and stems.
  • the method for producing the anaphylactic allergic symptom improving substance of the present invention comprises the steps of pulverizing and mixing Stevia plant tissue, placing the mixture in purified water, heating, stirring, cooling, and filtering to obtain a filtrate. It is obtained by concentrating under reduced pressure to obtain a stevia extract, fermenting this stevia extract with yeast.
  • the plant tissue of Stevia is a leaf and stem of Stevia.
  • the filtrate under reduced pressure has a sugar content of about 8.
  • the fermentation period is 10 days or more.
  • FIG. 1 is a flow chart showing a production process of the substance of the present invention.
  • the substance for improving the symptoms of anaphylactic allergy of the present invention is As Stevia rebaudiana Bertoni in South America.
  • the upper leaves and stems of Stevia about 15 cm above the ground, are used.
  • the leaves and stems are dried, and both dried leaves and stems are ground to less than 10 microns.
  • crushed stevia leaf and stem are mixed at a ratio of 3:10 to obtain a stevia mixture, and 1 kg of this stevia mixture is placed in 120 liters of purified water and heated from room temperature, often gently. The extraction is continued for several hours while stirring.
  • the mixture is cooled to room temperature, and then filtered with a size of 140 mesh to obtain a filtrate.
  • the filtrate is taken out and further heated and stirred at a temperature of about 80 ° C for about 1 hour.
  • the sugar content is about 8 degrees (concentration under reduced pressure to a solid concentration of about 8w / vtt.
  • the concentrated solution is further filtered to a size of about 0.45 micrometer or less.
  • the obtained filtrate is used as a stevia extract, which is used as a raw material.
  • the fermentation period is 10 days or more, preferably 10 days to 14 days. Filtrate the solution fermented for about 10 S with a size of 0.45 micrometer or less to make it a complete solution.
  • the liquid purified by the above method has an antihistamine action.
  • a pharmacological experiment was conducted on the antihistamine effect of the guinea pig isolated ileum specimen using the substance of the present invention thus obtained.
  • the liquid obtained by the above method was used as a test liquid (referred to as Stevia test liquid), and this test liquid was freeze-dried.
  • the obtained solid (referred to as Stevia solid) was dissolved in a Lock-Ringer solution and used.
  • Nutrient solution using lock Ringer solution (mM) (Lock- Ringer solution (mM)), composition N a C 1 1 5 4, KC 1 5. 6, C a C l 2 2. 2, Mg C l 2 2.1, Na HCO 35.9, Glucose 2.8 (pH 7.4).
  • the drugs used were Stevia test solution, histamine ( ⁇ ko) (histamine (Wako)), and diphenhydramine ( ⁇ ko) (diphenhydramine (Wako)). Stevia solids were dissolved in Lock-Ringer solution and applied directly to Magnus tubes. The results obtained were judged to be significantly different by a Dunnett's multiple comparison test with a risk factor of 5%. -As a result, the effect of stevia on the histamine contractile response was observed.
  • the substance of the present invention was made into a cream form (referred to as stevia cream) and an extract form (referred to as stevia extract), and a skin sticking test was performed as a skin safety test of the stevia cream and the stevia extract.
  • the present invention has clarified for the first time that a liquid produced by fermenting a stevia extract with a yeast bacterium has an antihistamine action. This effect was reversible observed from stevia solid 1 0- 5 g / ral or more concentrations. It was concluded that the antihistamine action of Stevia solid was a histamine H i (histamine H i) receptor blocking action. This mechanism of action is thought to be due to the fact that stevia solids bind to the histamine Hi receptor and suppress the histamine expression effect. It was shown that the liquid (Stevia test solution) produced by fermenting the stevia extract with yeast bacteria contained a compound showing an antihistamine action. If the substance of the present invention is anaphylactic allergy It has been shown to be effective in reducing symptoms for diseases such as hay fever, measles, bronchial asthma or atopy.
  • a substance capable of improving the symptoms of anaphylactic allergy could be obtained in a relatively short period of time by fermenting stevia extract with yeast.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'objectif de l'invention est d'obtenir de nouveaux agents destinés à soulager les réactions allergiques anaphylactiques ainsi qu'un nouveau procédé de production de ces agents. Pour produire ces derniers, on ajoute une levure à un extrait de stevia,obtenu par extraction à partir de tissus de stevia. A cet effet, les tissus de stevia sont moulus, mélangés, ajoutés à de l'eau purifiée et chauffés. Le produit obtenu est ensuite remué, refroidi et filtré. Le filtrat est alors concentré sous une pression réduite, pour produire un extrait de stevia. Ensuite, on ajoute de la levure à cet extrait de stevia que l'on fait fermenter.
PCT/JP2002/010918 2001-10-25 2002-10-22 Agents soulageant les reactions allergiques anaphylactiques, et leur procede de production Ceased WO2003035090A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001327372A JP2005035888A (ja) 2001-10-25 2001-10-25 アナフィラキシー型アレルギー症状改善物質およびその製造方法
JP2001/327372 2001-10-25

Publications (1)

Publication Number Publication Date
WO2003035090A1 true WO2003035090A1 (fr) 2003-05-01

Family

ID=19143613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010918 Ceased WO2003035090A1 (fr) 2001-10-25 2002-10-22 Agents soulageant les reactions allergiques anaphylactiques, et leur procede de production

Country Status (3)

Country Link
JP (1) JP2005035888A (fr)
KR (1) KR20030035768A (fr)
WO (1) WO2003035090A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010021001A3 (fr) * 2008-08-19 2010-04-29 Kaushik Ramakrishnan S Procédé de préparation d’un édulcorant à partir de stevia rebaudiana
WO2013093881A1 (fr) 2011-12-23 2013-06-27 L'oreal Utilisation cosmétique du stéviol, d'un dérivé glycoside de stéviol, ou d'un de leurs isomères pour stimuler, restaurer ou réguler le métabolisme des cellules de la peau et des membranes semi-muqueuses
WO2013093880A1 (fr) 2011-12-23 2013-06-27 L'oreal Utilisation de stéviol, d'un dérivé glycoside de stéviol, ou d'un de leurs isomères, pour prévenir, réduire et/ou traiter une altération du teint de la peau
WO2014132217A1 (fr) 2013-02-28 2014-09-04 L'oreal Composition comprenant du rébaudioside a et une cellulose substituée
WO2014132219A2 (fr) 2013-02-28 2014-09-04 L'oreal Composition contenant un rébaudioside a et un tensioactif oxyéthyléné
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9693961B2 (en) 2001-08-06 2017-07-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
US10525053B2 (en) 2002-07-05 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CN115379766A (zh) * 2020-02-14 2022-11-22 葡萄适利宾纳三得利有限公司 甜味成分

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100620854B1 (ko) * 2004-05-24 2006-09-14 박수상 스테비아 엑기스를 만드는 방법
JP4375758B2 (ja) * 2007-04-06 2009-12-02 株式会社シャローム 抗ヒスタミン物質およびその製造方法
JP6370608B2 (ja) * 2014-05-28 2018-08-08 株式会社シャローム 抗炎症性物質の製造方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0713021B2 (ja) * 1991-08-01 1995-02-15 文夫 堂園 消化器系疾患治療用内服薬剤
JPH08325156A (ja) * 1995-06-01 1996-12-10 Ichimaru Pharcos Co Ltd ステビオール配糖体含有皮膚外用剤及び飲食品
JPH10182425A (ja) * 1996-12-20 1998-07-07 Otsuka Yakuhin Kogyo Kk 活性浴剤の製造方法
JP2001131046A (ja) * 1999-11-04 2001-05-15 Pola Chem Ind Inc 過酸化水素消去剤及びこれを含有する化粧料。
JP2001151688A (ja) * 1999-11-25 2001-06-05 Ta Stevia Co Ltd ステビア濃縮液剤および皮膚病治療軟膏その製造方法
JP2001192342A (ja) * 2000-01-07 2001-07-17 Ta Stevia Co Ltd ステビア濃縮液剤および成熟ざくろ混合物の製造方法
EP0868917B1 (fr) * 1997-03-31 2001-12-05 Naohiko Sato Utilisation d'extraits de stévia pour la fabrication d'une composition antihistaminique
JP6092314B2 (ja) * 2008-04-24 2017-03-08 クゥアルコム・インコーポレイテッドＱｕａｌｃｏｍｍ Ｉｎｃｏｒｐｏｒａｔｅｄ ローカルｉｐアクセススキーム

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0713021B2 (ja) * 1991-08-01 1995-02-15 文夫 堂園 消化器系疾患治療用内服薬剤
JPH08325156A (ja) * 1995-06-01 1996-12-10 Ichimaru Pharcos Co Ltd ステビオール配糖体含有皮膚外用剤及び飲食品
JPH10182425A (ja) * 1996-12-20 1998-07-07 Otsuka Yakuhin Kogyo Kk 活性浴剤の製造方法
EP0868917B1 (fr) * 1997-03-31 2001-12-05 Naohiko Sato Utilisation d'extraits de stévia pour la fabrication d'une composition antihistaminique
JP2001131046A (ja) * 1999-11-04 2001-05-15 Pola Chem Ind Inc 過酸化水素消去剤及びこれを含有する化粧料。
JP2001151688A (ja) * 1999-11-25 2001-06-05 Ta Stevia Co Ltd ステビア濃縮液剤および皮膚病治療軟膏その製造方法
JP2001192342A (ja) * 2000-01-07 2001-07-17 Ta Stevia Co Ltd ステビア濃縮液剤および成熟ざくろ混合物の製造方法
JP6092314B2 (ja) * 2008-04-24 2017-03-08 クゥアルコム・インコーポレイテッドＱｕａｌｃｏｍｍ Ｉｎｃｏｒｐｏｒａｔｅｄ ローカルｉｐアクセススキーム

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TATSUHIKO KON ET AL.: "Antihistaminic effects of stevia fermenting extracts on isolated ileum from guinea pig", PHARMACOMETRICS (OYO YAKURI), vol. 62, no. 5/6, 2002, pages 105 - 109, XP002962329 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10500160B2 (en) 2001-08-06 2019-12-10 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9867784B2 (en) 2001-08-06 2018-01-16 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US11135171B2 (en) 2001-08-06 2021-10-05 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9872836B2 (en) 2001-08-06 2018-01-23 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10076497B2 (en) 2001-08-06 2018-09-18 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10071057B2 (en) 2001-08-06 2018-09-11 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9693961B2 (en) 2001-08-06 2017-07-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10064824B2 (en) 2001-08-06 2018-09-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10064825B2 (en) 2001-08-06 2018-09-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9968559B2 (en) 2001-08-06 2018-05-15 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9757341B2 (en) 2001-08-06 2017-09-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9877924B2 (en) 2001-08-06 2018-01-30 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9861582B2 (en) 2001-08-06 2018-01-09 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9861583B2 (en) 2001-08-06 2018-01-09 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10525053B2 (en) 2002-07-05 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10525052B2 (en) 2004-06-12 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
WO2010021001A3 (fr) * 2008-08-19 2010-04-29 Kaushik Ramakrishnan S Procédé de préparation d’un édulcorant à partir de stevia rebaudiana
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10966932B2 (en) 2010-12-22 2021-04-06 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9861584B2 (en) 2010-12-22 2018-01-09 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US9750703B2 (en) 2010-12-22 2017-09-05 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9744136B2 (en) 2010-12-22 2017-08-29 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US11590082B2 (en) 2010-12-22 2023-02-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9872837B2 (en) 2010-12-22 2018-01-23 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US11911512B2 (en) 2010-12-22 2024-02-27 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9895317B2 (en) 2010-12-23 2018-02-20 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
WO2013093880A1 (fr) 2011-12-23 2013-06-27 L'oreal Utilisation de stéviol, d'un dérivé glycoside de stéviol, ou d'un de leurs isomères, pour prévenir, réduire et/ou traiter une altération du teint de la peau
WO2013093881A1 (fr) 2011-12-23 2013-06-27 L'oreal Utilisation cosmétique du stéviol, d'un dérivé glycoside de stéviol, ou d'un de leurs isomères pour stimuler, restaurer ou réguler le métabolisme des cellules de la peau et des membranes semi-muqueuses
WO2014132219A2 (fr) 2013-02-28 2014-09-04 L'oreal Composition contenant un rébaudioside a et un tensioactif oxyéthyléné
WO2014132217A1 (fr) 2013-02-28 2014-09-04 L'oreal Composition comprenant du rébaudioside a et une cellulose substituée
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN115379766A (zh) * 2020-02-14 2022-11-22 葡萄适利宾纳三得利有限公司 甜味成分

Also Published As

Publication number Publication date
JP2005035888A (ja) 2005-02-10
KR20030035768A (ko) 2003-05-09

Similar Documents

Publication Publication Date Title
WO2003035090A1 (fr) Agents soulageant les reactions allergiques anaphylactiques, et leur procede de production
CN105054040B (zh) 一种益生菌发酵人参的组合物及其制备方法和应用
BRPI0612968A2 (pt) uso do Ácido benzàico e/ou seu sal de sàdio em combinaÇço com sacarÍdeos, composiÇço vaginal e mÉtodo para modular a flora vaginal e a acidez vaginal
CN108186784B (zh) 蒲公英复合酵素及其制备方法和用途
TW561049B (en) Crude drug extracts, and method for standardizing same
JPH05139984A (ja) 米からの活性酸素消去剤
JPH0987189A (ja) エンメイソウ、ボタンピ、シソ、アルニカ含有抗アレルギー剤
CN105663172A (zh) 一种生态妇科外用药物组合物及其制备方法和应用
KR101394524B1 (ko) 항히스타민 물질 및 그 제조 방법
KR20070062007A (ko) 쌀 또는 찹쌀 당화물의 발효액을 함유하는 항궤양 조성물및 그 제조방법
US20050112218A1 (en) Treatment of vulvovaginitis with spirostanol enriched extract from Tribulus Terrestris
US3988440A (en) Remedy for treating gastritis, gastric and duodenal ulcers
EP1784168A1 (fr) Procédé d"utilisation de compositions à base de plantes
TW201043609A (en) Application of Acacia extracts and their phytocompounds on the inhibition of xanthine oxidase
CN109069413B (zh) 用于治疗阴道真菌感染的葡萄糖酸δ-内酯
CN109674777A (zh) 异绿原酸类化合物在制备神经退行性疾病和忧郁症的药物中的应用
CN117503805A (zh) 基于黑皮鸡枞提取物组合物治疗溃疡性结肠炎的控释制剂
JP4450406B2 (ja) ベニカミキリフラスを有効成分とする皮膚外用薬
CN101559046A (zh) 小分子糖醇组合物对鼻部疾病的治疗作用
JPH037234A (ja) 生理活性物質、その製法、該物質を含有する薬剤、化粧品及び機能性食品
CN117442688A (zh) 一种降尿酸的药物组合物及其制备方法
CN116869892A (zh) 一种具有舒缓功效的植物组合物和精华液
CN111631991A (zh) 一种私密护理洗液
KR20000060083A (ko) 유산균 발효액 및 이를 함유하는 화장료 조성물
CN1435247A (zh) 治疗泌尿系统结石和尿路感染疾病的中药制剂及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase